RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy

Han, Zeyu; Yi, Xian; Jin, Li; Zhang, Tianyi; Liao, Daqing; You, Jing; Ai, Jianzhong

doi:10.1016/j.bbcan.2023.188961

Cited by 7 publications

(3 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes and the m6A modification have been confirmed as the key regulatory mechanism in PCa progression [ 20 , 28 – 30 ]. Herein, A1BG-AS1 was low-expressed in PCa and its overexpression attenuated the tumorigenic behavior of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Yang,

Luo,

Zhang

et al. 2024

Cell Div

View full text Add to dashboard Cite

Background Exosome-derived long non-coding RNAs (lncRNAs) and N6-methyladenosine (m6A) modifications of lncRNAs have been shown crucial functions in prostate cancer (PCa). Herein, we aim to investigate the detailed mechanism of exosome-derived lncRNA A1BG-AS1 in PCa process. Methods PCa cell exosomes were extracted, exosomal marker proteins (CD63, CD9) were detected utilizing western blotting, and exosomes with overexpressing A1BG-AS1 were co-cultured with targeted PCa cells. qRT-PCR was used to detect A1BG-AS1 expression and m6A methyltransferase ZC3H13 in PCa. Transwell, colony formation and CCK-8 assays were utilized to assess the invasion, migration, and proliferation ability of PCa cells. Then, we performed actinomycin D and MeRIP assays to analyze the regulatory effect of ZC3H13 on A1BG-AS1 mRNA stability and m6A modification level. Results We observed that A1BG-AS1 and ZC3H13 expression was restricted in PCa tumors. The invasion, proliferation and migratory capacities of PCa cells could be inhibited by up-regulating A1BG-AS1 or by co-culturing with exosomes that up-regulate A1BG-AS1. Additionally, ZC3H13 promoted stable A1BG-AS1 expression by regulating the m6A level of A1BG-AS1. Conclusion Exosomal A1BG-AS1 was m6A-modified by the m6A methyltransferase ZC3H13 to stabilize expression and thus prevent PCa cell malignancy. These findings offer a possible target for clinical therapy of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Yang,

Luo,

Zhang

et al. 2024

Cell Div

View full text Add to dashboard Cite

show abstract

“…However, the majority of the RNAs in the human genome are non-coding RNAs. The association between non-coding RNAs and PCa has not received ample attention ( 113 ). Non-coding RNAs are not only abundant, but also versatile ( 114 ).…”

Section: The M 6 a And Non-coding Rna Modificationsmentioning

confidence: 99%

“…This suggests that m 6 A modification may also be involved in the regulation of tumor-related genes. In addition, the association between changes in the expression levels of three types of partial regulators in PCa, and the development and progression of PCa have been demonstrated ( 113 , 127 ). The three regulators interact to specifically regulate RNA splicing, translation, stability and other aspects in an m 6 A-dependent manner, and promote specific biological behaviors such as proliferation, migration, and invasion of cancerous tissues.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6 -methyladenosine (m 6 A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6 A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6 A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6 A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6 A regulator to correct abnormal m 6 A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

show abstract

Deciphering the genetic and epigenetic architecture of prostate cancer

Nazir,

Mishra,

Maurya

et al. 2024

Advances in Cancer Research

View full text Add to dashboard Cite

RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy

Cited by 7 publications

References 141 publications

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Deciphering the genetic and epigenetic architecture of prostate cancer

Contact Info

Product

Resources

About

RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy

Cited by 7 publications

References 141 publications

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Deciphering the genetic and epigenetic architecture of prostate cancer

Contact Info

Product

Resources

About

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)